0RG8 Stock Chart & Stats
€197.30
-€1.90(-1.15%)
At close: 4:00 PM EDT
€197.30
-€1.90(-1.15%)
Day’s Range― - ―
52-Week Range€150.00 - €225.00
Previous CloseN/A
Volume97.94K
Average Volume (3M)46.18K
Market Cap
€20.50B
Enterprise Value€22.86B
Total Cash (Recent Filing)€172.00M
Total Debt (Recent Filing)€2.31B
Price to Earnings (P/E)63.1
Beta1.32
Next Earnings
Feb 23, 2027EPS Estimate
1.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.34
Shares Outstanding97,330,410
10 Day Avg. Volume13,818
30 Day Avg. Volume46,177
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€243.86Price Target Upside23.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)4.97
Revenue Forecast (FY)€3.14B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables And Installed BaseThe mix of frequently replaced consumables and installed equipment creates repeat purchasing beyond one-time capital sales. As biopharmaceutical customers expand production, this model can support durable customer relationships, recurring revenue, and greater visibility across future manufacturing cycles.
Healthy Operating MarginsGross and EBITDA margins remain healthy for the business, indicating meaningful value creation from its bioprocessing technologies, equipment, and consumables. These margins provide operating capacity to support research, product development, customer service, and growth investment over the next several quarters.
Improved Financial StabilityThe substantial reduction in debt-to-equity strengthens the balance sheet relative to 2023 and improves financial flexibility. Higher equity and lower relative leverage should make it easier to fund operations and strategic investment while reducing the balance-sheet strain associated with prior debt levels.
Bears Say
Weak Cash ConversionPositive operating and free cash flow are not converting efficiently from reported earnings, which reduces the quality and flexibility of profit generation. If this pattern persists, the company may have less internally generated cash available for investment, debt reduction, or shareholder returns.
Volatile Earnings RecoveryThe recovery demonstrates improvement, but the multi-year earnings profile remains volatile and is still described as being in a rebuild phase. Performance below the 2022 peak means future results remain sensitive to the pace of biopharmaceutical production growth and customer capacity expansion.
Meaningful Debt And Moderate ReturnsAlthough leverage has improved, the remaining debt burden is still material relative to the company’s current return profile. Moderate ROE suggests capital is not yet generating returns comparable with prior highs, limiting the strength of balance-sheet efficiency and leaving less room for execution setbacks.
Sartorius Stedim Biotech News
0RG8 FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest share price was €150.00 and its highest was €225.00 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €20.50B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Feb 23, 2027 which is in 121 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Oct 22, 2026. The company reported €1.18 earnings per share for the quarter, missing the consensus estimate of €1.209 by -€0.029.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech does not currently pay dividends.
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.47.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.18 in its last earnings report, missing expectations of €1.209. Following the earnings report the stock price went up 1.6%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in GB:0RG8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
0RG8 Stock 12 Month Forecast
Average Price Target
€243.86
▲(23.60% Upside)